Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

Company Overview - Arcutis is a dermatology-focused biotechnology company founded over 9 years ago to address the lack of innovation in the dermatology pipeline [2] - The company's lead product, ZORYVE, is a topical PDE4 inhibitor that is currently marketed and has three different formulations approved for four diseases [2] Product Details - ZORYVE includes a cream and foam formulation for plaque psoriasis, a foam for seborrheic dermatitis, and a different cream for atopic dermatitis [2] - The company anticipates approval for an expansion of the label in atopic dermatitis in October and is conducting a study for further label expansion [3] - Arcutis is nearing the filing for a label expansion for plaque psoriasis targeting additional patient populations [3]